Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 in Unresectable Stage III NSCLC
NCT07619911Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 2 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07619911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619911.